Chicago Atlantic BDC, Inc. (LIEN) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call shows mixed signals: strong financial performance with increased net investment and gross income, consistent dividends, and a solid pipeline. However, risks in the cannabis market, regulatory uncertainties, and unrealized losses pose challenges. Management's vague responses about the $500 million shelf registration also add uncertainty. The Q&A session highlighted both positive M&A prospects and concerns about execution risks. Overall, the sentiment is balanced between positive financial metrics and potential regulatory and market risks, leading to a neutral stock price prediction.
Key Financial Performance
Net Investment Income (NII) $10 million or $0.44 per share, up from $8.3 million or $0.36 per share in Q4 2025. This represents a year-over-year increase driven by higher interest income and fee income on strong deployments, partially offset by increased expenses.
Gross Investment Income $16.7 million, up from $14.2 million in Q4 2025. The increase was primarily due to higher interest income.
Net Expenses $6.7 million, up from $5.9 million in Q4 2025. The increase was driven by higher interest expenses from the utilization of the credit facility to fund new originations.
Net Unrealized Loss $1.4 million, attributed to the impact of widening spreads, not underlying credit performance.
Net Assets $304.2 million, a new high, with a Net Asset Value (NAV) per share of $13.33 compared to $13.30 in Q4 2025.
Debt Outstanding $54.5 million as of March 31, 2026, drawn from the revolving line of credit.
Weighted Average Yield on Debt Investments 15.8%, consistent with the previous quarter.
Loan Repayments and Amortization $63.4 million during Q1 2026, including $42.1 million in refinancings and $21.3 million in paydowns and amortization.
New Debt Investments Funded $93.9 million across 7 portfolio companies, including 3 new borrowers. 100% of these were senior secured, and 83% were fixed or floating rate loans at their respective floor.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Cannabis Market Expansion: The company funded $93.9 million across 7 portfolio companies, including 3 new borrowers, marking its most active origination period to date. The pipeline includes $482 million in cannabis opportunities, indicating significant growth potential in this market.
Non-Cannabis Market Expansion: The non-cannabis origination pipeline expanded to $328 million, reflecting increased strategic activity and financing demand in this sector.
Record Net Investment Income: Net investment income reached a record $10 million or $0.44 per share, driven by higher interest and fee income.
Portfolio Growth: The portfolio grew to its largest level in company history, with $54.5 million of debt and a 0.18x debt-to-equity ratio, significantly below the industry average of 1.3x.
Yield on Debt Investments: The weighted average yield on debt investments was 15.8%, compared to the public BDC average of 10.8%.
Liquidity and Financial Flexibility: The company had $51.5 million in liquidity and filed a shelf registration to issue up to $500 million in securities, enhancing financial flexibility.
Focus on Underserved Markets: The company continues to focus on underserved markets, particularly the cannabis industry, leveraging limited competition to achieve strong pricing power and downside protection.
Federal Cannabis Policy Shift: The Department of Justice announced plans to reschedule state-licensed medical cannabis products from Schedule I to Schedule III, potentially improving borrower credit quality and industry economics.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Uncertainty: The cannabis industry faces ongoing federal constraints and complexity, which could limit new large-scale lending competition and create challenges for borrowers.
Interest Rate Sensitivity: While 94% of the portfolio is insulated from interest rate declines, a 100 basis point drop in benchmark rates could still have a minor impact on interest income.
Credit Facility Utilization: Increased utilization of the credit facility has led to higher interest expenses, which could impact net investment income if not managed effectively.
Unrealized Losses: The company recognized a net unrealized loss of $1.4 million this quarter due to widening spreads, which, while not tied to credit performance, could affect portfolio valuation.
Cannabis Market Risks: The company’s focus on the cannabis industry exposes it to risks tied to regulatory changes, market volatility, and the financial health of cannabis operators.
Pipeline Execution Risks: The company has a significant pipeline of $810 million in potential debt transactions, but execution risks remain, especially in the cannabis sector.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Federal Cannabis Policy Changes: The Department of Justice announced that state-licensed medical cannabis products will be moved from Schedule I to Schedule III, eliminating the 280E tax code. This change is expected to improve cash flow and balance sheets for operators with medical cannabis market exposure. An administrative hearing on rescheduling recreational cannabis is scheduled for June 29, with a decision expected by July 15, potentially increasing capital markets and M&A activity.
Regulatory and Competitive Landscape: The company anticipates limited new large-scale lending competition in the near term due to ongoing federal constraints and industry complexity. It plans to maintain rigorous underwriting standards based on the current regulatory framework.
Origination Pipeline: The pipeline includes approximately $810 million in potential debt transactions, with $482 million in cannabis opportunities and $328 million in non-cannabis opportunities. Activity in cannabis is expected to increase throughout the year due to regulatory tailwinds and M&A appetite.
Liquidity and Financial Flexibility: The company filed a shelf registration statement with the SEC to issue up to $500 million in securities, including debt securities, to enhance liquidity and financial flexibility. This is expected to support shareholder returns and earnings.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Announcement: A $0.34 dividend was announced, marking the seventh consecutive quarter at that rate.
Dividend Sustainability: The company's performance supports a consistent dividend, leveraging its niche strategy and strong pricing power.
Shareholder Returns Strategy: The company filed a shelf registration statement with the SEC to issue up to $500 million in securities, including debt securities, to increase liquidity and support shareholder returns.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide more details on the $500 million shelf registration, particularly regarding the type of rates compared to the current revolver and timing for tapping the debt security market?
A:The shelf registration was filed primarily to raise debt in the future. It is too early to determine the rates or timing for raising capital.
Q:What leverage level are you comfortable with, given the BDC average of 1.3?
A:The company expects to stay well below the BDC average.
Q:Can you provide details on the growth of the non-cannabis pipeline and why the focus doesn't seem to be shifting more towards cannabis despite favorable regulatory news?
A:The non-cannabis origination pipeline grew significantly, but it is uncertain how much will transact. The cannabis portfolio is expected to grow due to increased M&A activity following recent regulatory news.
Q:For modeling purposes, can we assume full use of the revolver by the end of the year?
A:The company aims to make full use of the revolver by year-end.
Q:What is the average loan size for the three new portfolio companies, and are the smaller loans within your target range?
A:The non-cannabis portfolio comprises smaller loans by design, expected to range between 20%-30% of the portfolio. The smaller loan sizes are intentional.
Q:Are you seeing an increase in M&A activity due to rescheduling news, and is it more about public companies going private or private-to-private deals?
A:There is an increasing portion of the pipeline driven by M&A activity. While not all deals are large or public, there is significant interest and eagerness to capitalize on the current industry opportunity.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the rates and timing for raising capital through the $500 million shelf registration.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Atlantic trajectory
BDC lending
BDC position
BDC record
BDCs exposure
BDCs investment
Department Justice
III policy
Justice step
Kampf maam
Operators cannabis
SEC security
Sack Chicago
basis point
borrowing
cannabis industry
capacity credit
debt portfolio
drop
economics
environment
equity ratio
hearing
income record
increase interest
interest income
investment BDCs
line
market competition
market exposure
portfolio investment
portfolio value
protection
quality
rate basis
record share
rescheduling
LIEN Transcript
Chicago Atlantic BDC, Inc. (LIEN) Q1 2026 Earnings Call Transcript
Unknown5-14
The earnings call shows mixed signals: strong financial performance with increased net investment and gross income, consistent dividends, and a solid pipeline. However, risks in the cannabis market, regulatory uncertainties, and unrealized losses pose challenges. Management's vague responses about the $500 million shelf registration also add uncertainty. The Q&A session highlighted both positive M&A prospects and concerns about execution risks. Overall, the sentiment is balanced between positive financial metrics and potential regulatory and market risks, leading to a neutral stock price prediction.
Chicago Atlantic BDC, Inc. (LIEN) Q4 2025 Earnings Call Transcript
Positive3-19
The earnings call indicates strong financial health with a high yield on debt investments and a low debt-to-equity ratio. The company's pipeline growth and optimism from industry rescheduling are positive signs. Despite a slight decrease in gross investment income, the NAV per share increased, reflecting stability. The Q&A highlights increased transaction activity and potential growth opportunities, further supporting a positive sentiment.
Chicago Atlantic BDC, Inc. (LIEN) Q3 2025 Earnings Call Transcript
Positive11-13
The company demonstrates strong financial performance with increased net investment income and a high yield on debt investments. The dividend is well-covered and consistent, indicating robust shareholder returns. Despite regulatory risks and competitive pressures, the firm maintains a positive outlook on the cannabis market, leveraging its strong pipeline and relationship-building efforts. Management's responses in the Q&A suggest a proactive approach to market challenges, and the financial metrics indicate a solid foundation for growth. These factors collectively support a positive sentiment towards the stock price over the next two weeks.
Chicago Atlantic BDC, Inc. (LIEN) Q2 2025 Earnings Call Transcript
Unknown8-14
The earnings call summary presents a mixed picture: strong financial performance with record debt investments and stable dividends, but significant risks in the cannabis sector and regulatory uncertainty. While the Q&A reveals optimism in the cannabis market, it also highlights unclear regulatory responses. The stable dividend and strong investment income are positives, but the concentrated risk in cannabis and potential regulatory impacts suggest a balanced outlook. Thus, the stock price is likely to remain neutral in the short term.
LIEN Slides
LIEN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
